KCNJ16 and glioblastoma: Without using the history of seizure medications, a difference in expression of KCNJ16/Kir5.1 in glioblastomas (less expression), p = 0.05, became significant in glioblastomas using the smaller group of patients on anti-seizure drugs; p = 0.0148.